Amarantus Bioscience Holdings Inc (AMBS)

[ferdilopje]

However, in 2013 the stock teetered briefly on the edge, then started slipping back down to what may be a more realistic price for a company with next to no cash and a medical product in deep pre-clinical testing. As of the date of their latest quarterly report from September 2012, AMBS had the following:

$580 in cash
$4.6 million in current liabilities
$564 thousand in quarterly net loss